Evidence map›Paper›PMID 28935977›Full record

ArticleScientific reports2017

Zebrafish In-Vivo Screening for Compounds Amplifying Hematopoietic Stem and Progenitor Cells: - Preclinical Validation in Human CD34+ Stem and Progenitor Cells.

Guruchandar Arulmozhivarman, Martin Kräter, Manja Wobus, Jens Friedrichs, Elham Pishali Bejestani, Katrin Müller, Katrin Lambert, Dimitra Alexopoulou, Andreas Dahl, Martin Stöter and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Role ofInternational journal of molecular sciences · 2020
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Guruchandar ArulmozhivarmanDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany.
Martin KräterDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany.ORCID 0000-0001-7122-7331
Manja WobusDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany.
Jens FriedrichsInstitute of Biofunctional Polymer Materials, Leibniz Institute for Polymer Research, Max Bergmann Center of Biomaterials, Dresden, Germany.
Elham Pishali BejestaniGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Katrin MüllerDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany.
Katrin LambertDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany.
Dimitra AlexopoulouDeep Sequencing Group SFB655, Biotechnology Center, Technical University of Dresden, Dresden, Germany.
Andreas DahlDeep Sequencing Group SFB655, Biotechnology Center, Technical University of Dresden, Dresden, Germany.ORCID 0000-0002-2668-8371
Martin StöterMax-Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Marc BickleMax-Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.ORCID 0000-0002-8918-1869
Nona ShayegiDepartment of Hematology, University Hospital Essen, University of Duisburg, Essen, Germany.
Jochen HampeDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany.ORCID 0000-0002-2421-6127
Friedrich StölzelDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany.
Michael BrandDFG-Center for Regenerative Therapies Dresden (CRTD) - Cluster of Excellence, Technical University of Dresden, Dresden, Germany. michael.brand@biotec.tu-dresden.de.
Malte von BoninDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany.ORCID 0000-0002-3828-0031
Martin BornhäuserDepartment of Hematology/Oncology, Medical Clinic and Policlinic I, University Hospital, Dresden, Germany. martin.bornhaeuser@uniklinikum-dresden.de.
Technische Universität Dresden · DEGerman Cancer Research Center · DEMax Planck Institute of Molecular Cell Biology and Genetics · DELeibniz Institute of Polymer Research · DEStädtisches Klinikum Dresden · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of small molecules that either increase the number and/or enhance the activity of human hematopoietic stem and progenitor cells (hHSPCs) during ex vivo expansion remains challenging. We used an unbiased in vivo chemical screen in a transgenic (c-myb:EGFP) zebrafish embryo model and identified histone deacetylase inhibitors (HDACIs), particularly valproic acid (VPA), as significant enhancers of the number of phenotypic HSPCs, both in vivo and during ex vivo expansion. The long-term functionality of these expanded hHSPCs was verified in a xenotransplantation model with NSG mice. Interestingly, VPA increased CD34

Indexed as

AnimalsAntigens, CD34Cell ProliferationCells, CulturedDrug Evaluation, PreclinicalGraft SurvivalHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansMice, Inbred NODMice, KnockoutMice, SCIDSmall Molecule LibrariesTransplantation, HeterologousValproic AcidAntigens, CD34Histone Deacetylase InhibitorsSmall Molecule LibrariesValproic Acid

Identifiers

PMID28935977
PMCPMC5608703
OpenAlexW2755693918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.